A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT05592275 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

332

Enrollment

INDUSTRY

Sponsor class

Stopped An interim was conducted and after review of available data, including efficacy evaluation of heart failure events, Lilly is terminating the study due to low likelihood of study success for this HFpEF patient population.

Conditions

Heart Failure
Heart Failure With Preserved Ejection Fraction

Interventions

DRUG: LY3540378
DRUG: Placebo

Sponsor

Eli Lilly and Company